← 產業報告目錄
Autoimmune Polyglandular Syndrome Type 1 Market Size, Share & Trends Analysis Report By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests, Others), Age of Onset (Childhood, Adult, Adolescent), Treatment (Medication, Hormone Replacement Therapy, Others), Dosage Form (Tablet, Capsule, Others), Route of Administration, End-Users, Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 180報告編號 INSIGHTACE-abe19f80f3
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 244.1 Mn as of 2023, the global Autoimmune Polyglandular Syndrome Type 1 Market is projected to climb to USD 389.6 Mn by 2031, reflecting a compound annual growth rate of 6.20% over the 2024–2031 period.
Autoimmune Polyglandular Syndrome Type 1 encompasses an uncommon autosomal recessive disorder characterized by hypoparathyroidism, adrenal insufficiency, and chronic mucocutaneous candidiasis. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Market momentum is bolstered by surging need advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Autoimmune Polyglandular Syndrome Market Snapshot
Chapter 4. Global Autoimmune Polyglandular Syndrome Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Diagnosis Estimates & Trend Analysis
5.1. by Diagnosis & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Diagnosis:
5.2.1. Serum Autoimmune Screen
5.2.2. End-organ Function Tests
5.2.3. Blood Tests
5.2.4. Others
Chapter 6. Market Segmentation 2: by Treatment Estimates & Trend Analysis
6.1. by Treatment & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Treatment:
6.2.1. Medication
6.2.2. Antifungal Agents
6.2.3. Fluconazole
6.2.4. Itraconazole
6.2.5. Calcitriol
6.2.6. Corticosteroids
6.2.7. Hormone Replacement Therapy
6.2.8. Others
Chapter 7. Market Segmentation 3: by Dosage Form Estimates & Trend Analysis
7.1. by Dosage Form & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Dosage Form:
7.2.1. Tablet
7.2.2. Capsule
7.2.3. Others
Chapter 8. Market Segmentation 4: by Route of Administration Estimates & Trend Analysis
8.1. by Route of Administration & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Route of Administration;
8.2.1. Oral
8.2.2. Others
Chapter 9. Market Segmentation 5: by Age of Onset Estimates & Trend Analysis
9.1. by Age of Onset & Market Share, 2019 & 2031
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Age of Onset;
9.2.1. Childhood
9.2.2. Adult
9.2.3. Adolescent
Chapter 10. Market Segmentation 6: by Distribution Channel Estimates & Trend Analysis
10.1. by Distribution Channel & Market Share, 2019 & 2031
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel;
10.2.1. Hospital Pharmacy
10.2.2. Retail Pharmacy
10.2.3. Online Pharmacy
10.2.4. Others
Chapter 11. Market Segmentation 7: by End-Users Estimates & Trend Analysis
11.1. by End-Users & Market Share, 2019 & 2031
11.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-Users:
11.2.1. Hospitals
11.2.2. Specialty Clinics
11.2.3. Homecare
11.2.4. Others
Chapter 12. Autoimmune Polyglandular Syndrome Market Segmentation 8: Regional Estimates & Trend Analysis
12.1. North America
12.1.1. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.1.2. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.1.3. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.1.4. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
12.1.5. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.1.6. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.1.7. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.1.8. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
12.2. Europe
12.2.1. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.2.2. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.2.3. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.2.4. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
12.2.5. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.2.6. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.2.7. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.2.8. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
12.3. Asia Pacific
12.3.1. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.3.2. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.3.3. Asia-Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.3.4. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
12.3.5. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.3.6. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.3.7. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.3.8. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
12.4. Latin America
12.4.1. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.4.2. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.4.3. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.4.4. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration,2019-2031
12.4.5. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.4.6. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.4.7. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.4.8. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
12.5. Middle East & Africa
12.5.1. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.5.2. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.5.3. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.5.4. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
12.5.5. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.5.6. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.5.7. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.5.8. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Pfizer Inc. (U.S.)
13.2.2. GlaxoSmithKline plc (U.K.)
13.2.3. Novartis AG (Switzerland)
13.2.4. Mylan N.V. (U.S.)
13.2.5. Teva Pharmaceutical Industries Ltd
13.2.6. Sanofi (France)
13.2.7. F. Hoffmann-La Roche Ltd. (Switzerland)
13.2.8. Zydus Cadila (India)
13.2.9. Lupin (India)
13.2.10. Amneal Pharmaceuticals LLC. (U.S.)
13.2.11. Cipla Inc. (U.S.)
13.2.12. Aurobindo Pharma (India)
13.2.13. Glenmark Pharmaceuticals Limited
13.2.14. Eli Lilly and Company (U.S.)
13.2.15. Sun Pharmaceutical Industries Ltd.
13.2.16. Allergan (Ireland)
13.2.17. Bristol-Myers Squibb Company (U.S.)
13.2.18. Takeda Pharmaceutical Company Limited
13.2.19. Abbott (U.S.)
13.2.20. LEO Pharma A/S (Denmark)
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們